Studies have shown that immune checkpoints such as immunosuppressants PD-1 and CTLA4 show important value in inhibiting the occurrence and development of a variety of malignant tumors (Shojaie et al., 2021; Yi et al., 2021). Here, CTLA4 is linked to cancer.